Boston Scientific Prices $3.0B and €4.25B Senior Notes to Fund Penumbra Deal
BSX is trading near its 52-week low of $39.57 (6.1% above the low).
Summary
Boston Scientific priced $3.0 billion of USD notes and €4.25 billion of euro notes to fund the cash consideration for its Penumbra acquisition, with a 101% special mandatory redemption if the deal does not close. The financing is debt-only, so there is no equity dilution.
Key Events · Financing and Capital Events · BSX
-
Dual-Currency Debt Offering Priced
The company priced $3.0 billion of USD senior notes across four series (5.375% due 2029, 5.500% due 2031, 5.750% due 2033, 5.875% due 2036) and €4.25 billion of euro notes across six series, including a €500 million floating-rate note due 2028.
-
Proceeds Fund Penumbra Cash Consideration
Net proceeds, together with short-term borrowings and cash on hand, will finance the cash consideration for the previously announced Penumbra acquisition and related fees.
-
101% Special Mandatory Redemption
Each series must be redeemed at 101% of principal plus accrued interest if the Penumbra acquisition is not completed by the outside date (January 14, 2027, extendable to no later than January 14, 2028) or if the company abandons the deal.
-
Closing Set for December 1, 2026
Both offerings are expected to close December 1, 2026, subject to customary conditions; neither offering is conditioned on the other or on completion of the Penumbra acquisition.
Analysis · BSX · Industrial Applications And Services
Boston Scientific has locked in $3.0 billion of dollar notes and €4.25 billion of euro notes — roughly $8 billion of new debt at blended coupons in the 4-6% range — to fund the cash portion of its previously announced Penumbra acquisition. Because the financing is debt rather than equity, there is no share dilution; the trade-off is higher interest expense and leverage at a company already absorbing a costly cyberattack that cut Q3 gross margin to 66.7%. Bondholders are protected if the Penumbra deal falls through by a 101% special mandatory redemption, which also signals that management treats the acquisition as the base case. Watch the December 1, 2026 closing and any rating-agency commentary on the added leverage.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSX was trading at $41.98 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $60.9B. The 52-week trading range was $39.57 to $101.91. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.